434 results about "Drugs sensitivity" patented technology

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit / hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

A generic model structure captures basic characteristics in BIS-based patients' responses to anesthesia and surgical stimulation, the model being used in combination with the insight of an anesthesiologist. The model structure represents the patient response with a time delay, a time constant for response speed, and a nonlinear function for drug sensitivity. Clinical data confirms the model structure and is used to establish parameters and function forms for individual patients. A feedback and predictive control strategy for anesthesia drug infusion is then introduced on the basis of the patient model. Feedback control alone cannot avoid large fluctuations in BIS values when significant surgical stimulation is imposed, as a result of time delays in a patient's response to drug infusion. Predictive control attenuates fluctuations of BIS levels from surgical stimulation.

The present invention provides compositions useful in treating drug-resistant microorganisms and cells, as well as related methods of identifying and using such compositions. In addition, the present invention includes compositions useful in enhancing the sensitivity of both drug-resistant and drug-sensitive microorganisms and cells to microbicidal and cytotoxic agents, including antibiotics and chemotherapeutic drugs. Methods of identifying these compositions, as well as methods of using these agents in treating both drug-resistant and drug-sensitive diseases and conditions are further provided.

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and / or who have undergone adjuvant therapy are also provided herein.

This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.

The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells. Methods for identifying molecular targets for drug screening, identifying interacting gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.

The invention belongs to the technical field of helicobacter pylori (Hp) examination and discloses a kit for fast culture, identification and a drug sensitivity test of Hp and an examination method therefor. The kit comprises a first culture tube, an identification reagent device and a drug sensitivity test unit. Through the first culture tube of Hp, bedside inoculation of a specimen is realized and the traditional sample transport and preservation processes are avoided; ordinary thermostat culture is realized and dependence on a CO2 incubator is eliminated; an Hp growth result is represented by a color change so that a result can be determined accurately by laypeople; through the combination of a growth promoting agent and a growth indicator, culture time is shortened and fast culture of Hp is realized; an Hp identification reagent, fast combination identification of Hp is realized; and through the drug sensitivity test unit of Hp, fast and accurate examination of drug sensitivity of Hp is realized. The kit and the examination method therefor can realize fast and accurate examination of Hp.

The invention discloses a drug sensitivity prediction method for cancer precision treatment. Anti-cancer drug sensitivity prediction is performed by comprehensively utilizing genomics data of cell lines, so that theoretical medication guidance is provided for individual treatment. A calculation model is built for predicting drug sensitivity to individuals, thereby guiding clinical medication, which is one of core goals of precision treatment. According to the method, interaction terms among genes are added by utilizing a protein interaction network; a mutual relationship among the cell lines is described by utilizing the similarity of gene expression profiles of the cell lines; a local weighted linear model is built without depending on an independence assumption among genomic characteristics; and compared with a conventional linear model, a better prediction effect is achieved, the problem of high-latitude input caused by large-scale data characteristics is solved, and the operation cost of the model is reduced. The method can be widely applied to the drug sensitivity prediction of new cell lines, and provides the theoretical guidance for guiding the clinical medication.

The invention belongs to the field of biological medicines and relates to an application of combination of a Caspase activator and an oncolytic virus in preparation of an antitumor drug. The condition that the antitumor effect of the oncolytic virus can be improved with the Caspase activator is discovered for the first time, the combination of the Caspase activator and the oncolytic virus has a quite high synergistic effect, and an effective therapeutic schedule is provided for oncotherapy with low drug sensitivity.

The invention provides a 5-fluorouracil drug sensitivity gene chip detection kit, which can be used to parallelly and economically detect genes related to 5-fluorouracil drug sensitivity. The kit comprises an extraction solution, a hybridization buffer solution, a washing liquor, an amplifying solution, Taq enzyme and a gene chip, the amplifying solution contains a primer for amplifying four genes containing mutant sites, and the four genes include a DPD gene containing IVS14 A / G mutant sites, a GSTPi gene containing Ile105Val mutant sites, an MTHFR gene containing C677T mutant sites, and an XRCC1 gene containing Arg399Glu mutant sites. The 5 fluorouracil is a first-line anti-tumor chemotherapeutic drug, and the detection kit can be used for detecting the four gene mutation conditions sensitive to the 5 fluorouracil drug.

Described herein is a network biology approach useful for the identification of multiple therapeutic targets, which can be targeted simultaneously using an agent (or a plurality of agents) to modulate cellular phenotypes, or in combination with pharmaceutical compounds to improve drug sensitivity and / or reduce drug doses to maintain efficacy while minimizing side effects. The preferred approach disclosed herein relies on first identifying the mediators of a condition of interest, and second, selecting gene combinations that are in competing / parallel pathways as targets for combination therapy.

The invention provides a breast cancer multidrug-resistant cell strain constructed by virtue of epirubicin induction, wherein the breast cancer multidrug-resistant cell strain has a collection number of CCTCC C201439. The invention further provides a method for constructing the breast cancer multidrug-resistant cell strain. According to the invention, an MDA-MB-231 / EPI drug-resistant strain is successfully established, wherein a drug-resistant index is 26.27 times, and obvious cross resistance is produced for taxol, etoposide and cis-platinum. A drug-resistant tumor cell model is provided for the following related researches so as to research drug-resistant tumor cell morphology and biological characteristics, research a tumor multidrug resistance mechanism, analyze sensitivity to chemotherapeutic drugs as well as screen chemotherapeutic drugs, develop tumor drug resistant reverse drugs and research and develop a more effective tumor therapeutic method, and the like.

The invention discloses a bacteria drug-resistance detection system and an operation method thereof. The system comprises a drug sensitive test inoculation instrument, drug sensitive test image acquisition conversion equipment, a drug sensitivity detection kit and a bacterial strain culture device. A medium is arranged in the drug sensitivity detection kit. The drug sensitive test inoculation instrument is used for inoculating a bacterial strain into the drug sensitivity detection kit. The bacterial strain culture device provides a growth environment for the bacterial strain in the drug sensitivity detection kit. The drug sensitive test image acquisition conversion equipment is used for acquiring and converting images of the bacterial strain in the drug sensitivity detection kit. Management software is arranged in the drug sensitive test image acquisition conversion equipment, and the management software is connected to the network. With combination of online and offline, clinical medication is directly guided. The system meets on-site detection requirements, is convenient for data analysis and decision-making for a farm, a veterinary medicines factory and an administrative department, is suitable for current high-level drug resistance situation in our country, and satisfies the need of quantitative networked monitoring of drug resistance. A broth dilution method and an agar dilution method are both considered. The system meets different requirements of large-scale monitoring and scattered sample detection.

Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate analysis with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the respective genes to drug sensitivity was determined to select genes with a high degree of contribution. In addition, the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values determined experimentally. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens associated with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).

The invention relates to an anti-tumor drug screening kit based on a three-dimensional micro-tissue level and an application method thereof. The anti-tumor drug screening kit comprises a three-dimensional cell culture material, a tissue cell dispersion reagent, a proteinase inhibitor, a basic cell culture medium, blood serum, antibiotics, a balance salt solution, a cell activity detection reagentand a cell filter screen. The application method comprises the following steps: dispersing tumor tissues of a patient to obtain tissue blocks, tissue fragments, cell aggregates and / or dispersed singlecells; then culturing the dispersed tumor tissues of the patient and a cell sample through a three-dimensional culture method and enabling the cells to grow in a three-dimensional space to form a spherical structure or an irregular three-dimensional structure with a stereoscopic shape; finally, carrying out a drug sensitivity test on tumor micro-tissues obtained by three-dimensional culture. Theanti-tumor drug screening kit based on the three-dimensional micro-tissue level is simple to operate and is suitable for the drug sensitivity tests of various solid tumors.

Amooranin (AMR) has been found to cause tumor cell death through G2 / m cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.

The invention relates to the technical field of myeoplasmapneumoniae (Mp) detection and discloses a kit for fast culture, identification and a drug sensitivity test of Mp and a detection method therefor. The kit comprises a culture tube, a drug sensitivity identification plate and a container unit containing sterile mineral oil. A base liquid, a growth promoting agent, a growth indicator and an impurity bacterium inhibitor are arranged in the culture tube. The drug sensitivity identification plate comprises an identification zone and a drug sensitivity test zone. Through the impurity bacterium inhibitor adopted by a culture solution formula, a false positive problem caused by bacteria and fungi is solved. Through the growth promoting agent and the growth indicator adopted by the culture solution formula, a problem of overlong detection time is solved. Through the identification zone, a false positive problem caused by other mycoplasmas is solved. Through the drug sensitivity test zone, a fast and accurate drug sensitivity test of Mp is realized. Therefore, the kit can effectively avoid false positive and has a short detection period.

The invention discloses a novel application of honokiol and fluconazole in antifungal cooperation. According to the invention, the fungi are candida albicans. According to the invention, a standard macrodilution drug sensitivity experiment recommended by CLSI is adopted, in vitro sensitivity of honokiol towards clinically separated drug resistant candida albicans is evaluated with systematic methods such as a checkerboard macrodilution method and a time-kill curve method. Also, an in vitro synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated. Further, with a mice infection and treatment experiment, an in vivo synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated.

The invention relates to a fast drug sensitivity detection kit for vibrio, which can be applied to an aquiculture site. According to the invention, the detection kit comprises a detection plate, a thallus collection tool, bacterium enrichment liquid, a drug sensitivity detection culture medium, a turbidimetry tube, an inoculation burette and a colorimetric card, wherein the detection plate comprises inspection holes enveloping drugs and color indicators for drug sensitivity detection, and the color indicators are Alamar Blue. According to the invention, fish peptone, Ca2+ and Mg2+ are added based on the MH culture medium and the concentration of NaCl is adjusted, and the culture medium is used as the bacterium enrichment liquid of vibrio, which can effectively promote the growth of the vibrio and enables the bacterium enrichment liquid to reach the required concentration in a short time, so as to shorten the time of drug sensitivity detection. At the same time, a blue dye, namely the Alamar Blue, which is safe and nontoxic to the cells is used; the Alamar Blue has no toxic effect on cells, and can be enveloped in the micropores of the drug sensitivity detection plate directly without influencing the growth of the bacteria, so that the detection operation is simpler and more convenient and quick; and the proliferation dynamic of the bacteria can be continuously monitored.

A method is disclosed for assaying the sensitivity of neoplastic tissue to therapeutic agents, and in particular, for the quantification of pro-apoptotic marker mRNA expression in cells obtained from thinly-sliced living tumor tissue in such methods. The method may comprise ascertaining a particular apoptosis marker mRNA for an individual tumor or tumor type as well as exposure of thin-sliced live cancer tissues from the individual tumor to candidate chemotherapeutic drug regimes in vitro, followed by an assessment of the level of the marker mRNA in the tissue.

Living cells can be stably modified to emit different colors from the cytoplasm and nucleus, thus permitting analysis of the status of said cells and the effect of agents on said cells either by visual or instrumentally-aided observation. These observations may be made, if desired, in real time. In addition, rates of proliferation and drug sensitivities can be determined in vitro in real time by the use of cells modified to express a single fluorescent protein and observing fluorescence intensity as a function of time.

The invention relates to a preparation method for a drug sensitivity kit and a drug sensitivity detection method, which are applied in the field of aquiculture. The drug sensitivity kit comprises a centrifuge tube with enriched bacterial culture solution, a culture dish with solid culture medium and a drug sensitivity drug storage ring. According to the invention, drug sensitivity detection is carried out on suscepts and water samples and the drug sensitivity drug storage rings are observed after the detection; drugs in drug sensitivity plasters where a transparent area appears can all be used as alternative drugs, and the drug in a drug sensitivity plaster where a big clear area appears can be used as a preferable drug; therefore a most appropriate antibiotic is selected out. Using a drug based on a correct diagnosis can avoid abuse of fish drugs and particularly abuse of antibiotics, and prevent medicinal residues from remaining in aquatic products. It only needs 12 hours to complete the preparation of the drug sensitivity kit; thus selection of drugs and corresponding prevention and treatment can be carried out in a same day as the preparation. The invention has the advantages of simple and convenient operation and low cost, is applicable to selection of drugs for controlling bacterial diseases in basic level of aquiculture, and plays a positive role in protecting ecological environment for aquiculture.

The invention relates to the field of biotechnology, in particular to an organoid culture medium and an organoid culture method. The organoid culture medium comprises a base medium, hydrothorax supernatant, enzyme hydrolyzed casein, hydrocortisone, l-glutamic acid, insulin, transferrin, cholera viruses, Y-27632, EGF, amphotericin B, penicillin and streptomycin. The organoid culture method includesperforming two-dimensional culture on tumor cells, and performing three-dimensional culture on the cultured cells to form organoid tissue. The medium formula can promote the rapid proliferation of tumor tissue while avoiding hypoxia injuries, and the culture method can greatly shorten the time required for a subsequent drug sensitivity test; the accuracy of the drug sensitivity test is improved,and the test cost is reduced.

The invention discloses a method for utilizing a malignant pleural effusion for separately culturing primary cancer cells. The method comprises the steps of putting a pleural effusion sample into a sample collecting liquid, and centrifuging to remove a supernatant; adding a red blood cell lysis buffer for removing a red blood cell, adding a PBS buffer solution for washing the cells, and centrifuging to remove a supernatant; using a KL culture medium for resuspending a cell precipitate, inoculating in a culture flask, and culturing in a culture box. When the cells are proliferated to more than85 percent of abundance, the cells are washed through the PBS buffer solution, pancreatin-EDTA is digested, and a stop buffer neutralizes digestion reaction; the cells are centrifugally collected, areresuspended through the KL culture medium, and inoculated in the cell flask according to the proportion so as to be subcultured. The primary cancer cells of the pleural effusion obtained by separatedculture through the method provided by the invention can be applied to related research of physiology, pharmacy, new drug research and development and the like, exploration of pathogenesis of relateddiseases of a lung cancer, detection of drug sensitivity of different drugs, screening of anti-cancer drugs, new drug research and development, and establishment of a personalized treatment program aiming at a patient.

The present invention comprises a treatment approach based on gene set-expression signatures that systematically connects a sample to a profile from a reference database to extrapolate the most effective therapeutic agent. Further disclosed are methods to optimize combination treatments.

It is herewith provided methods of obtaining circulating cancer cells (CCCs)-enriched cellular populations based on the removal of CD45-positive cells from an apheresis product. It is also provided methods of obtaining circulating stem cells (CSCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection either using the specific cellular markers or through culture. It is further provided methods of obtaining circulating tumor cells (CTCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection using the specific cellular markers. It is also provided screening assays for the selection of (chemo)therapeutic agent as well as personalized medicine application based on drug sensitivity / resistance or cancer markers.

The invention discloses a drug sensitivity prediction method based on cell line and drug similarity networks, which comprises the steps of: constructing the drug similarity network, the cell line similarity network and a drug-cell line relationship network; respectively acquiring a drug adjacent matrix, a cell line adjacent matrix and a drug-cell line relationship initial matrix according to the drug similarity network, the cell line similarity network and the drug-cell line relationship network; and based on the drug adjacent matrix, the cell line adjacent matrix and the drug-cell line relationship initial matrix, obtaining a drug-cell line drug sensitivity prediction matrix by adopting an unbalanced double random walk algorithm, wherein each element in the drug-cell line drug sensitivityprediction matrix obtained after walk is completed by adopting an unbalanced double random walk formula is a predicted sensitivity value of a corresponding drug for a cell line. According to the invention, characteristics of the drug similarity network and the cell line similarity network are sufficiently considered, so that reliability of a drug sensitivity prediction result is improved.

Diagnostic and therapeutic methods of cancer treatment and prevention using metabolic profiling compounds that contain [1,2-13C2]-D-glucose, and kits for using such metabolic profiling compounds.